GlaxoSmithKline Market Cap 2006-2018 | GSK

GlaxoSmithKline market cap history and chart from 2006 to 2018. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of diluted shares outstanding. GlaxoSmithKline market cap as of November 20, 2018 is $101.26B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $101.256B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
Novartis AG (NVS) Switzerland $204.655B 17.49
AbbVie (ABBV) United States $134.597B 11.95
Eli Lilly (LLY) United States $122.680B 21.57
Sanofi (SNY) France $112.713B 13.96
Novo Nordisk (NVO) Denmark $111.107B 18.04
AstraZeneca (AZN) United Kingdom $103.342B 12.83
Bristol-Myers Squibb (BMY) United States $87.290B 14.38